Listenly

What enforcement actions have occurred against research-only peptide sellers?

Answered at 15:56 in Peptides, Telemedicine, Pharmacy & Compliance: The Future of Peptide Healthcare · B2B Vault: The Biz To Biz Podcast

— questions searchable right now

What enforcement actions have occurred against research-only peptide sellers?

Research-only peptide companies have faced fines ranging from $50,000 to $200,000, with enforcement escalating dramatically in some cases. One company paid over $70 million in a settlement with pharmaceutical companies and faced up to seven years in jail, with employees also required to pay back money.

The Scale of Enforcement Against Illegal Peptide Operations

The penalties vary based on the severity of violations, but the baseline enforcement sends a clear message: operating illegally in the research peptide space carries serious financial consequences. As Angela Salter explains on the podcast, companies operating outside the regulatory framework face immediate FTC and FDA intervention.

The most severe case documented involved a research-only peptide company that not only paid millions in civil penalties but also faced criminal charges resulting in jail sentences for executives. This reflects a coordinated enforcement effort between federal agencies and pharmaceutical companies protecting their intellectual property and market interests.

"We certify based on current applicable laws and regulations, not what a committee thinks might be true in a year or two."

Angela Salter — Vice President of Enterprise Certification Sales and Partnerships at LegitScript. Angela oversees enterprise customers and account management for certification clients, as well as strategic partnerships with payment processors and advertising platforms like Visa and MasterCard that require LegitScript certification for telemedicine and pharmacy merchants.

Allen Kopelman on B2B Vault: The Biz To Biz PodcastAll answers from this podcast →
Full answer and detailsRead the whole answer, key facts and every other question from this episode

In short

Research-only peptide companies have faced fines ranging from $50,000 to $200,000, with enforcement escalating dramatically in some cases.

Allen Kopelman · Peptides, Telemedicine, Pharmacy & Compliance: The Future of Peptide Healthcare · B2B Vault: The Biz To Biz Podcast · answer at 15:56

Key takeaways

  • One company paid over $70 million in a settlement with pharmaceutical companies and faced up to seven years in jail, with employees also required to pay back money.
  • The penalties vary based on the severity of violations, but the baseline enforcement sends a clear message: operating illegally in the research peptide space carries serious financial consequences.
  • The most severe case documented involved a research-only peptide company that not only paid millions in civil penalties but also faced criminal charges resulting in jail sentences for executives.
  • Angela Salter — Vice President of Enterprise Certification Sales and Partnerships at LegitScript.

Quote to remember

“We certify based on current applicable laws and regulations, not what a committee thinks might be true in a year or two.”

— Allen Kopelman

The full answer · about 1 min

Research-only peptide companies have faced fines ranging from $50,000 to $200,000, with enforcement escalating dramatically in some cases. One company paid over $70 million in a settlement with pharmaceutical companies and faced up to seven years in jail, with employees also required to pay back money.

The Scale of Enforcement Against Illegal Peptide Operations

The penalties vary based on the severity of violations, but the baseline enforcement sends a clear message: operating illegally in the research peptide space carries serious financial consequences. As Angela Salter explains on the podcast, companies operating outside the regulatory framework face immediate FTC and FDA intervention.

The most severe case documented involved a research-only peptide company that not only paid millions in civil penalties but also faced criminal charges resulting in jail sentences for executives. This reflects a coordinated enforcement effort between federal agencies and pharmaceutical companies protecting their intellectual property and market interests.

"We certify based on current applicable laws and regulations, not what a committee thinks might be true in a year or two."

Angela Salter — Vice President of Enterprise Certification Sales and Partnerships at LegitScript. Angela oversees enterprise customers and account management for certification clients, as well as strategic partnerships with payment processors and advertising platforms like Visa and MasterCard that require LegitScript certification for telemedicine and pharmacy merchants.

More answers from this episode

 ·  All answers from B2B Vault: The Biz To Biz Podcast →
—
—
0:00
0:00